JCT  Vol.3 No.6 , December 2012
Monoclonal Antibodies: An Emerging Class of Therapeutics in Non Small Cell Lung Cancer
ABSTRACT
Lung cancer is the leading cause of cancer-related deaths in industrialized countries and non small cell lung cancer (NSCLC) accounts for 85% of all lung cancers. Cisplatin doublet based chemotherapy, which is the recommended regimen in first line therapy in advanced or metastatic NSCLC, improves survival but in low proportion. Monoclonal antibodies (mAbs) are a novel promising therapeutic class used with great results in inflammatory diseases such as rheumatoid arthritis. Antibodies are natural proteins with modular structure, specific pharmacodynamics and pharmacokinetics and possibly produced against any antigens, thus giving them several advantages over small drug therapeutics. In solid tumors, therapeutic mAbs improved progression free survival (PFS) and overall survival (OS) of patients with breast and colon cancers and had considerably changed the treatment in clinical practice. In NSCLC, bevacizumab, an anti-VEGF mAb, and cetuximab, an anti-EGFR mAb, are the most studied antibodies. Bevacizumab acts on angiognenesis and improved PFS of non squamous NSCLC but in low proportion as shown in two large phase III trials. It was approved by European Medicines Agency (EMEA) and Food and Drug administration (FDA) as a first line therapy in combination with cisplatin doublet chemotherapy. Cetuximab slightly enhanced OS but did not improve PFS in two large phase III trials. These results added to high adverse effect lead to cetuximab refusal by EMEA and FDA in NSCLC. At first glance, the results of mAbs in NSCLC are somewhat disappointing, in contrast to the benefits obtained with mAb treatments in other solid tumors. However, many other mAbs directed against novel targets, such as IGF1-R or CTLA-4, and new mAbs targeting VEGFR and EGFR pathways with different pharmacodymamical and pharmacokinetic properties are under evaluation and may change our vision of taking care of patients with NSCLC. In conclusion, it seems that mAbs therapy in NSCLC clearly marks the start of a new era in NSCLC treatment, with promises in improving patient survival and quality of life.

Cite this paper
L. Guilleminault, E. Lemarié and N. Heuzé-Vourc’h, "Monoclonal Antibodies: An Emerging Class of Therapeutics in Non Small Cell Lung Cancer," Journal of Cancer Therapy, Vol. 3 No. 6, 2012, pp. 1170-1190. doi: 10.4236/jct.2012.36153.
References
[1]   R. Govindan, N. Page, D. Morgensztern, W. Read, R. Tierney, A. Vlahiotis, E. L. Spitznagel and J. Piccirillo, “Changing Epidemiology of Small-Cell Lung Cancer in the United States over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database,” J. Clin. Oncol., Vol. 24, No. 28, 2006, pp. 4539-4544. Doi:10.1200/JCO.2005.04.4859

[2]   C. G. Azzoli, S. Temin, T. Aliff, S. Baker Jr., J. Brahmer, D. H. Johnson, J. L. Laskin, G. Masters, D. Milton, L. Nordquist, W. Pao, D. G. Pfister, S. Piantadosi, J. H. Schiller, R. Smith, T. J. Smith, J. R. Strawn, D. Trent and G. Giaccone, “2011 Focused Update of 2009 American Soci y of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer,” Journal of Clinical Oncology, Vol. 29, No. 28, 2011, pp. 3825-3831. Doi:10.1200/JCO.2010.34.2774

[3]   S. G. Spiro, R. M. Rudd, R. L. Souhami, J. Brown, D. J. Fairlamb, N. H. Gower, L. Maslove, R. Milroy, V. Napp, M. K. B. Parmar, M. D. Peake, R. J. Stephens, H. Thorpe, D. A. Waller and P. West, “Chemotherapy versus Supportive Care in Advanced Non-Small Cell Lung Cancer: Improved Survival without d Riment to Quality of Life,” Thorax, Vol. 59, No. 10, 2004, pp. 828-836. Doi:10.1136/thx.2003.020164

[4]   D. J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W. Eiermann, J. Wolter, M. Pegram, J. Baselga and L. Norton, “Use of Chemotherapy plus a moNoclonal Antibody against HER2 for m Astatic Breast Cancer That Overexpresses HER2,” New England Journal of Medicine, Vol. 344, No. 11, 2001, pp. 783-792. Doi:10.1056/NEJM200103153441101

[5]   H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, J. Berlin, A. Baron, S. Griffing, E. Holmgren, N. Ferrara, G. Fyfe, B. Rogers, R. Ross and F. Kabbinavar, “Bevacizumab plus iriNotecan, Fluorouracil, and Leucovorin for m Astatic Colorectal Cancer,” New England Journal of Medicine, Vol. 350, No. 23, 2004, pp. 2335-2342. Doi:10.1056/NEJMoa032691

[6]   G. W. Litman, J. P. Rast, M. J. Shamblott, R. N. Haire, M. Hulst, W. Roess, R. T. Litman, K. R. Hinds-Frey, A. Zilch and C. T. Amemiya, “Phylogenetic Diversification of Immunoglobulin Genes and the Antibody Repertoire,” Molecular Biology and Evolution, Vol. 10, No. 1, 1993, pp. 60-72.

[7]   F. Winau, O. Westphal and R. Winau, “Paul Ehrlich—In Search of the Magic Bullet,” Microbes and Infection, Vol. 6, No. 8, 2004, pp. 786-789. Doi:10.1016/j.micinf.2004.04.003

[8]   G. K?hler and C. Milstein, “Continuous Cultures of Fused Cells Secring Antibody of Predefined Specificity,” Nature, Vol. 256, No. 5517, 1975, pp. 495-497. Doi:10.1038/256495a0

[9]   D. L. Shawler, R. M. Bartholomew, L. M. Smith and R. O. Dillman, “Human Immune Response to Multiple Injections of Murine moNoclonal IgG,” Journal of Immunology, Vol. 135, No. 2, 1985, pp. 1530-1535.

[10]   D. R. Getts, M. T. Getts, D. P. McCarthy, E. M. L. Chastain and S. D. Miller, “Have We Overestimated the Benefit of Human(ized) Antibodies?” MAbs, Vol. 2, No. 6, 2010, pp. 682-694. Doi:10.4161/mabs.2.6.13601

[11]   G. L. Boulianne, N. Hozumi and M. J. Shulman, “Production of Functional Chimaeric Mouse/Human Anti-body,” Nature, Vol. 312, No. 5995, 1984, pp. 643-646. Doi:10.1038/312643a0

[12]   P. T. Jones, P. H. Dear, J. Foote, M. S. Neuberger and G. Winter, “Replacing the Complementarity-Determining Regions in a Human Antibody with Those from a Mouse,” Nature, Vol. 321, No. 6069, 1986, pp. 522-525. Doi:10.1038/321522a0

[13]   S. J. Kim, Y. Park and H. J. Hong, “Antibody Engineering for the Development of Therapeutic Antibodies,” Molecules and Cells, Vol. 20, No. 1, 2005, pp. 17-29.

[14]   W. Y. K. Hwang and J. Foote, “ImmuNogenicity of Engineered Antibodies,” Methods, Vol. 36, No. 1, 2005, pp. 3-10. Doi:10.1016/j.ymeth.2005.01.001

[15]   E. Kaneko and R. Niwa, “Optimizing Therapeutic Anti-body Function: Progress with Fc Domain Engineering,” BioDrugs, Vol. 25, No. 1, 2011, pp. 1-11. Doi:10.2165/11537830-000000000-00000

[16]   K. A. Gelderman, S. Tomlinson, G. D. Ross and A. Gorter, “Complement Function in mAb-Mediated Cancer ImmuNotherapy,” Trends in Immunology, Vol. 25, No. 3, 2004, pp. 158-164. Doi:10.1016/j.it.2004.01.008

[17]   M. Watanabe, P. K. Wallace, T. Keler, Y. M. Deo, C. Akewanlop and D. F. Hayes, “Antibody Dependent Cellular Phagocytosis (ADCP) and Antibody Dependent Cellular Cytotoxicity (ADCC) of Breast Cancer Cells Mediated by Bispecific Antibody, MDX-210,” Breast Cancer Research and Treatment, Vol. 53, No. 3, 1999, pp. 199-207. Doi:10.1023/A:1006145507567

[18]   D. M. Goldenberg, “Targeted Therapy of Cancer with Radiolabeled Antibodies,” Journal of Nuclear Medicine, Vol. 43, No. 5, 2002, pp. 693-713.

[19]   F. R. Brennan, L. D. Morton, S. Spindeldreher, A. Kiessling, R. Allenspach, A. Hey, P. Y. Muller, W. Frings and J. Sims, “Safety and Immunotoxicity Assessment of Immunomodulatory Monoclonal Antibodies,” MAbs, Vol. 2, No. 3, 2010, pp. 233-255. Doi:10.4161/mabs.2.3.11782

[20]   T. T. Hansel, H. Kropshofer, T. Singer, J. A. Mitchell and A. J. T. George, “The Safety and Side Effects of Monoclonal Antibodies,” Nature Reviews Drug Discovery, Vol. 9, No. 4, 2010, pp. 325-338. Doi:10.1038/nrd3003

[21]   P. J. Bugelski, R. Achuthanandam, R. J. Capocasale, G. Treacy and E. Bouman-Thio, “MoNoclonal Antibody-Induced Cytokine-Release Syndrome,” Expert Review of Clinical Immunology, Vol. 5, No. 5, 2009, pp. 499-521. Doi:10.1586/eci.09.31

[22]   R. J. Keizer, A. D. R. Huitema, J. H. M. Schellens and J. H. Beijnen, “Clinical Pharmacokin Ics of Therapeutic Monoclonal Antibodies,” Clinical Pharmacokinetics, Vol. 49, No. 8, 2010, pp. 493-507. Doi:10.2165/11531280-000000000-00000

[23]   T. T. Kuo, K. Baker, M. Yoshida, S.-W. Qiao, V. G. Aveson, W. I. Lencer and R. S. Blumberg, “Neonatal Fc Receptor: From Immunity to Therapeutics,” Journal of Clinical Immunology, Vol. 30, No. 6, 2010, pp. 777-789. Doi:10.1007/s10875-010-9468-4

[24]   L. H. Stockwin and S. Holmes, “Antibodies as Therapeutic Agents: Vive la Renaissance!” Expert Opinion on Biological Therapy, Vol. 3, No. 7, 2003, pp. 1133-1152. Doi:10.1517/14712598.3.7.1133

[25]   J. M. Reichert, “Which Are the Antibodies to Watch in 2012?” MAbs, Vol. 4, No. 1, 2012, pp. 1-3. Doi:10.4161/mabs.4.1.18719

[26]   N. Ferrara, H.-P. Gerber and J. LeCouter, “The Biology of VEGF and Its Receptors,” Nature Medicine, Vol. 9, No. 6, 2003, pp. 669-676. Doi:10.1038/nm0603-669

[27]   G. Fontanini, L. Boldrini, S. Chinè, F. Pisaturo, F. Basolo, A. Calcinai, M. Lucchi, A. Mussi, C. A. Angeletti and G. Bevilacqua, “Expression of Vascular Endothelial Growth Factor mRNA in Non-Small-Cell Lung Carcinomas,” British Journal of Cancer, Vol. 79, No. 2, 1999, pp. 363-369. Doi:10.1038/sj.bjc.6690058

[28]   K. Kadota, C.-L. Huang, D. Liu, M. UeNo, Y. Kushida, R. Haba and H. Yokomise, “The Clinical Significance of Lymphangiogenesis and Angiogenesis in Non-Small Cell Lung Cancer Patients,” European Journal of Cancer, Vol. 44, No. 7, 2008, pp. 1057-1067. Doi:10.1016/j.ejca.2008.03.012

[29]   P. Zhan, J. Wang, X. Lv, Q. Wang, L. Qiu, X. Lin, L. Yu and Y. Song, “Prognostic Value of Vascular Endothelial Growth Factor Expression in Patients with Lung Cancer: A Systematic Review with Meta-Analysis,” Journal of Thoracic Oncology, Vol. 4, No. 9, 2009, pp. 1094-1103. Doi:10.1097/JTO.0b013e3181a97e31

[30]   L. G. Presta, H. Chen, S. J. O’ConNor, V. Chisholm, Y. G. Meng, L. Krummen, M. Winkler and N. Ferrara, “Humanization of an Anti-Vascular Endothelial Growth Factor Monoclonal Antibody for the Therapy of Solid Tumors and Other Disorders,” Cancer Research, Vol. 57, No. 20, 1997, pp. 4593-4599.

[31]   D. H. Johnson, L. Fehrenbacher, W. F. Novotny, R. S. Herbst, J. J. Nemunaitis, D. M. Jablons, C. J. Langer, R. F. DeVore III, J. Gaudreault, L. A. Damico, E. Holmgren and F. Kabbinavar, “Randomized Phase II Trial Comparing Bevacizumab plus Carboplatin and Paclitaxel with Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer,” Journal of Clinical Oncology, Vol. 22, No. 11, 2004, pp. 2184-2191. Doi:10.1200/JCO.2004.11.022

[32]   J. D. Hainsworth, L. Fang, J. E. Huang, D. Karlin, K. Russell, L. Faoro and C. Azzoli, “BRIDGE: An Open-Label Phase II Trial Evaluating the Safety of Bevacizumab + Carboplatin/Paclitaxel as First-Line Treatment for Patients with Advanced, Previously Untreated, Squamous Non-Small Cell Lung Cancer,” Journal of Thoracic Oncology, Vol. 6, No. 1, 2011, pp. 109-114. Doi:10.1097/JTO.0b013e3181f94ad4

[33]   R. S. Heist, P. Fidias, M. Huberman, B. Ardman, L. V. Sequist, J. S. Temel and T. J. Lynch, “A Phase II Study of Oxaliplatin, Pemetrexed, and Bevacizumab in Previously Treated Advanced Non-Small Cell Lung Cancer,” Journal of Thoracic Oncology, Vol. 3, No. 10, 2008, pp. 1153-1158. Doi:10.1097/JTO.0b013e318187273f

[34]   P. Correale, C. Remondo, S. F. Carbone, V. Ricci, C. Migali, I. Martellucci, A. Licchetta, R. Addeo, L. Volterrani, G. Gotti, M. S. Rotundo, P. Tassone, P. Sperlongano, A. Abbruzzese, M. Caraglia, P. Tagliaferri and G. Francini, “Dose/Dense Metronomic Chemotherapy with Fractioned Cisplatin and Oral Daily Etoposide Enhances the Anti-Angiogenic Effects of Bevacizumab and Has Strong Antitumor Activity in Advanced Non-Small-Cell-Lung Cancer Patients,” Cancer Biology & Therapy, Vol. 9, No. 9, 2010, pp. 685-693.

[35]   W. N. William Jr., M. S. Kies, F. V. Fossella, D. D. Liu, G. Gladish, W. H. Tse, J. J. Lee, W. K. Hong, S. M. Lippman and E. S. Kim, “Phase 2 Study of Carboplatin, Docetaxel, and Bevacizumab as Frontline Treatment for Advanced Nonsmall-Cell Lung Cancer,” Cancer, Vol. 116, No. 10, 2010, pp. 2401-2408. Doi:10.1097/JTO.0b013e3181f1d23c

[36]   C. Clément-Duchêne, Y. Krupitskaya, K. Ganjoo, P. Lavori, A. McMillan, A. Kumar, G. Zhao, S. Padda, L. Zhou, M. S. Pedro-Salcedo, A. D. Colevas and H. A. Wakelee, “A Phase II First-Line Study of Gemcitabine, Carboplatin, and Bevacizumab in Advanced Stage Non-squamous Non-Small Cell Lung Cancer,” Journal of Thoracic Oncology, Vol. 5, No. 11, 2010, pp. 1821-1825.

[37]   A. Sandler, R. Gray, M. C. Perry, J. Brahmer, J. H. Schiller, A. Dowlati, R. Lilenbaum and D. H. Johnson, “Paclitaxel-Carboplatin Alone or with Bevacizumab for Non-Small-Cell Lung Cancer,” New England Journal of Medicine, Vol. 355, No. 24, 2006, pp. 2542-2550. Doi:10.1056/NEJMoa061884

[38]   M. Reck, J. von Pawel, P. Zatloukal, R. Ramlau, V. GorbouNova, V. Hirsh, N. Leighl, J. Mezger, V. Archer, N. Moore and C. Manegold, “Phase III Trial of Cisplatin plus Gemcitabine with either Placebo or Bevacizumab as First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAil,” Journal of Clinical Oncology, Vol. 27, No. 8, 2009, pp. 1227-1234. Doi:10.1200/JCO.2007.14.5466

[39]   L. Crinò, E. Dansin, P. Garrido, F. Griesinger, J. Laskin, N. Pavlakis, D. Stroiakovski, N. Thatcher, C.-M. Tsai, Y. Wu and C. Zhou, “Safety and Efficacy of First-Line Bevacizumab-Based Therapy in Advanced Non-Squamous Non-Small-Cell Lung Cancer (SAiL, MO19390): A Phase 4 Study,” Lancet Oncology, Vol. 11, No. 8, 2010, pp. 733-740. Doi:10.1016/S1470-2045(10)70151-0

[40]   S. S. Ramalingam, S. E. Dahlberg, C. J. Langer, R. Gray, C. P. Belani, J. R. Brahmer, A. B. Sandler, J. H. Schiller and D. H. Johnson, “Outcomes for Elderly, Advanced-Stage Non Small-Cell Lung Cancer Patients Treated with Bevacizumab in Combination with Carboplatin and Paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599,” Journal of Clinical Oncology, Vol. 26, No. 1, 2008, pp. 60-65. Doi:10.1200/JCO.2007.13.1144

[41]   N. B. Leighl, P. Zatloukal, J. Mezger, R. Ramlau, N. Moore, M. Reck and C. Manegold, “Efficacy and Safety of Bevacizumab-Based Therapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-Small Cell Lung Cancer in the Phase III BO17704 Study (AVAiL),” Journal of Thoracic Oncology, Vol. 5, No. 12, 2010, pp. 1970-1976. Doi:10.1097/JTO.0b013e3181f49c22

[42]   J. Laskin, L. Crinò, E. Felip, F. Franke, V. Gorbunova, H. Groen, G.-L. Jiang, M. Reck and C.-P. Schneider, “Safety and Efficacy of First-Line Bevacizumab plus Chemotherapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-Small Cell Lung Cancer: Safety of Avastin in Lung Trial (MO19390),” Journal of Thoracic Oncology, Vol. 7, No. 1, 2012, pp. 203-211. Doi:10.1097/JTO.0b013e3182370e02

[43]   J. Zhu, D. B. Sharma, S. W. Gray, A. B. Chen, J. C. Weeks and D. Schrag, “Carboplatin and Paclitaxel with vs without Bevacizumab in Older Patients with Advanced Non-Small Cell Lung Cancer,” JAMA, Vol. 307, No. 15, 2012, pp. 1593-1601. Doi:10.1001/jama.2012.454

[44]   J. D. Patel, T. A. Hensing, A. Rademaker, E. M. Hart, M. G. Blum, D. T. Milton and P. D. Bonomi, “Phase II Study of Pemetrexed and Carboplatin plus Bevacizumab with Maintenance Pemetrexed and Bevacizumab as First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer,” Journal of Clinical Oncology, Vol. 27, No. 20, 2009, pp. 3284-3289. Doi:10.1200/JCO.2008.20.8181

[45]   J. D. Patel, P. BoNomi, A. C. Girvan and S. C. Guba, “Treatment Rationale and Study Design for the Pointbreak Study: A Randomized, Open-Label Phase III Study of Pemetrexed/Carboplatin/Bevacizumab Followed by Maintenance Pemetrexed/Bevacizumab versus Pacli-taxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer,” Clinical Lung Cancer, Vol. 10, No. 4, 2009, pp. 252-256. Doi:10.3816/CLC.2009.n.035

[46]   D. Galetta, S. Pisconti, A. Febbraro and G. Colucci, “Induction Pemetrexed and Cisplatin Followed by Maintenance Pemetrexed versus Carboplatin plus Paclitaxel plus Bevacizumab Followed by Maintenance Bevacizumab: A Quality of Life-Oriented Randomized Phase III Study in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer (ERA-CLE),” Clinical Lung Cancer, Vol. 12, No. 6, 2011, pp. 402-406. Doi:10.1016/j.cllc.2011.06.006

[47]   R. G. Zinner, S. B. Saxman, G. Peng, M. J. Monberg and W. I. Ortuzar, “Treatment Rationale and Study Design for a Randomized Trial of Pemetrexed/Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients with Advanced Non-Small-Cell Lung Cancer of Nonsquamous Histology,” Clinical Lung Cancer, Vol. 11, No. 5, 2010, pp. 352-357. Doi:10.3816/CLC.2010.n.045

[48]   C. Bankhead, “AVAPERL Trial Tests NSCLC Maintenance Regimens,” Clinical Oncology, Vol. 6, No. 12, 2011.

[49]   F. A. Shepherd, J. R. Pereira, T. Ciuleanu, E. H. Tan, V. Hirsh, S. Thongprasert, D. Campos, S. Maoleekoonpiroj, M. Smylie, R. Martins, M. van Kooten, M. Dediu, B. Findlay, D. Tu, D. Johnston, A. Bezjak, G. Clark, P. Santabárbara and L. Seymour, “Erlotinib in Previously Treated Non-Small-Cell Lung Cancer,” New England Journal of Medicine, Vol. 353, No. 2, 2005, pp. 123-132. Doi:10.1056/NEJMoa050753

[50]   R. S. Herbst, R. Ansari, F. Bustin, P. Flynn, L. Hart, G. A. Otterson, G. Vlahovic, C.-H. Soh, P. O’ConNor and J. Hainsworth, “Efficacy of bevacizumab plus Erlotinib versus Erlotinib Alone in Advanced Non-Small-Cell Lung Cancer after Failure of Standard First-Line Chemotherapy (BeTa): A Double-Blind, Placebo-Controlled, Phase 3 Trial,” Lancet, Vol. 377, No. 9780, 2011, pp. 1846-1854. Doi:10.1016/S0140-6736(11)60545-X

[51]   R. S. Herbst, D. H. Johnson, E. Mininberg, D. P. Carbone, T. Henderson, E. S. Kim, G. Blumenschein Jr., J. J. Lee, D. D. Liu, M. T. Truong,“Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor moNoclonal Antibody Bevacizumab in Combination with the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients with Recurrent Non-Small-Cell Lung Cancer,” Journal of Clinical On- cology, Vol. 23, No. 11, 2005, pp. 2544-2555. doi:10.1200/JCO.2005.02.477

[52]   R. S. Herbst, V. J. O’Neill, L. Fehrenbacher, C. P. Belani, P. D. BoNomi, L. Hart, O. Melnyk, D. Ramies, M. Lin and A. Sandler, “Phase II Study of Efficacy and Safety of Bevacizumab in Combination with Chemotherapy or Erlotinib Compared with Chemotherapy Alone for Treatment of Recurrent or Refractory Non Small-Cell Lung Cancer,” Journal of Clinical Oncology, Vol. 25, No. 30, 2007, pp. 4743-4750. Doi:10.1200/JCO.2007.12.3026

[53]   A.-M. C. Dingemans, A. J. de Langen, V. van den Boogaart, J. T. Marcus, W. H. Backes, H. T. G. M. Scholtens, H. van Tinteren, O. S. Hoekstra, J. Pruim, B. Brans, F. B. Thunnissen, E. F. Smit and H. J. M. Groen, “First-Line Erlotinib and Bevacizumab in Patients with Locally Advanced and/or Metastatic Non-Small-Cell Lung Cancer: A Phase II Study Including Molecular Imaging,” Annals of Oncology, Vol. 22, No. 3, 2011, pp. 559-566. Doi:10.1093/annonc/mdq391

[54]   V. A. Miller, P. O’ConNor, C. Soh and F. Kabbinavar, “A Randomized, Double-Blind, Placebo-Controlled, Phase IIIb Trial (ATLAS) Comparing Bevacizumab (B) Therapy with or without Erlotinib (E) after Completion of Chemotherapy with B for First-Line Treatment of Locally Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC),” Journal of Clinical Oncology, Vol. 27, 2009, p. 8002.

[55]   A. M. Jubb, H. I. Hurwitz, W. Bai, E. B. Holmgren, P. Tobin, A. S. Guerrero, F. Kabbinavar, S. N. Holden, W. F. Novotny, G. D. Frantz, K. J. Hillan and H. Koeppen, “Impact of Vascular Endothelial Growth Factor-A Expression, Thrombospondin-2 Expression, and Microvessel Density on the Treatment Effect of Bevacizumab in Metastatic Colorectal Cancer,” Journal of Clinical Oncology, Vol. 24, No. 2, 2006, pp. 217-227. Doi:10.1200/JCO.2005.01.5388

[56]   A. Dowlati, R. Gray, A. B. Sandler, J. H. Schiller and D. H. Johnson, “Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non-Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab—An Eastern Cooperative Oncology Group Study,” Clinical Cancer Research, Vol. 14, No. 5, 2008, pp. 1407-1412. Doi:10.1158/1078-0432.CCR-07-1154

[57]   S. E. Dahlberg, A. B. Sandler, J. R. Brahmer, J. H. Schiller and D. H. Johnson, “Clinical Course of Advanced Non-Small-Cell Lung Cancer Patients Experiencing Hypertension during Treatment with Bevacizumab in Combination with Carboplatin and Paclitaxel on ECOG 4599,” Journal of Clinical Oncology, Vol. 28, No. 6, 2010, pp. 949-954. Doi:10.1200/JCO.2009.25.4482

[58]   S. V. Kozin, Y. Boucher, D. J. Hicklin, P. Bohlen, R. K. Jain and H. D. Suit, “Vascular Endothelial Growth Factor Receptor-2-Blocking Antibody Potentiates Radiation-Induced Long-Term Control of Human Tumor Xenografts,” Cancer Research, Vol. 61, No. 1, 2001, pp. 39-44.

[59]   ImClone LLC, “A Study of Ramucirumab with Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer,” In: National Library of Medicine (US), ClinicalTrials.gov, Bethesda, 2000. http://clinicaltrials.gov/show/NCT00735696NLMIdentifier: NCT00735696

[60]   ImClone LLC, “Eli Lilly and Company. A Study in Second Line Non Small Cell Lung Cancer,” National Library of Medicine (US), ClinicalTrials.gov, Bethesda, 2000. http://clinicaltrials.gov/show/NCT01168973NLMIdentifier: NCT01168973

[61]   ImClone LLC, “A Study of Pemetrexed & Carboplatin/Cisplatin or Gemcitabine & Carboplatin/Cisplatin with or without imc-1121b in Patients Previously Untreated with Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC),” National Library of Medicine (US), ClinicalTrials.gov, Bethesda, 2000. http://clinicaltrials.gov/show/NCT01160744 NLM Identifier: NCT01160744

[62]   D. L. Daleke, “Regulation of Transbilayer Plasma Membrane Phospholipid Asymmetry,” Journal of Lipid Research, Vol. 44, No. 2, 2003, pp. 233-242. Doi:10.1194/jlr.R200019-JLR200

[63]   R. Digumarti, G. S. Bhattacharyya, L. Dasappa, J. Shan; Nizams Institute of Medical Sciences, Hyderabad, India; Yashoda Hospital, Hyderabad, India; Orchid Nursing Home, Kolkata, India; Kidwai Institute of Oncology, Bangalore, India; Peregrine Pharmaceuticals, Inc. and C. A. Tustin, “Phase II Study of Bavituximab plus Paclitaxel and Carboplatin in Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Interim Results,” Journal of Clinical Oncology, Vol. 28, No 15s, 2010, Abstr 7589.

[64]   Peregrine Pharmaceuticals, “Study of Paclitaxel/Carboplatin with or without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer,” National Library of Medicine (US). ClinicalTrials.gov, Bethesda, 2000. http://clinicaltrials.gov/show/NCT01160601NLMIdentifier NCT01160601

[65]   Peregrine Pharmaceuticals, “Study of Bavituximab plus Docetaxel in Patients with Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer,” National Library of Medicine (US), ClinicalTrials.gov, Bethesda, 2000. http://clinicaltrials.gov/show/NCT01138163NLM Identifier NCT01138163

[66]   N. E. Hynes and H. A. Lane, “ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors,” Nature Reviews Cancer, Vol. 5, No. 5, 2005, pp. 341-354. Doi:10.1038/nrc1609

[67]   V. Rusch, D. Klimstra, E. Venkatraman, P. W. Pisters, J. Langenfeld and E. Dmitrovsky, “Overexpression of the Epidermal Growth Factor Receptor and Its Ligand Transforming Growth Factor Alpha Is Frequent in Resectable Non-Small Cell Lung Cancer but Does Not Predict Tumor Progression,” Clinical Cancer Research, Vol. 3, No. 4, 1997, pp. 515-522.

[68]   G. Carpenter and S. Cohen, “Epidermal Growth Factor,” Annual Review of Biochemistry, Vol. 48, 1979, pp. 193-216. Doi:10.1146/annurev.bi.48.070179.001205

[69]   E. Tzahar, H. Waterman, X. Chen, G. Levkowitz, D. Karunagaran, S. Lavi, B. J. Ratzkin and Y. Yarden, “A Hierarchical Network of Interreceptor Interactions Determines Signal Transduction by Neu Differentiation Factor/Neuregulin and Epidermal Growth Factor,” Molecular and Cellular Biology, Vol. 16, No. 10, 1996, pp. 5276-5287.

[70]   M. Tateishi, T. Ishida, S. KohdoNo, M. Hamatake, Y. Fukuyama and K. Sugimachi, “Prognostic Influence of the Co-Expression of Epidermal Growth Factor Receptor and c-erbB-2 Protein in Human Lung Adenocarcinoma,” Surgical Oncology, Vol. 3, No. 2, 1994, pp. 109-113. Doi:10.1016/0960-7404(94)90006-X

[71]   P. Heinmoller, C. Gross, K. Beyser, C. Schmidtgen, G. Maass, M. Pedrocchi and J. Ruschoff, “HER2 Status in Non-Small Cell Lung Cancer: Results from Patient Screening for Enrollment to a Phase II Study of Herceptin,” Clinical Cancer Research, Vol. 9, No. 14, 2003, pp. 5238-5243.

[72]   D. Tan, G. Deeb, J. Wang, H. K. Slocum, J. Winston, S. Wiseman, A. Beck, S. Sait, T. Anderson, C. Nwogu, N. Ramnath and G. Loewen, “HER-2/neu Protein Expression and Gene Alteration in Stage I-IIIA Non-Small-Cell Lung Cancer: A Study of 140 Cases Using a Combination of High Throughput Tissue Microarray, Immunohistochemistry, and Fluorescent in Situ Hybridization,” Diagnostic Molecular Pathology, Vol. 12, No. 4, 2003, pp. 201-211. Doi:10.1097/00019606-200312000-00004

[73]   C. Pellegrini, M. Falleni, A. Marchetti, B. Cassani, M. Miozzo, F. Buttitta, M. Roncalli, G. Coggi and S. Bosari, “HER-2/Neu Alterations in Non-Small Cell Lung Cancer: A Comprehensive Evaluation by Real Time Reverse Transcription-PCR, Fluorescence in Situ Hybridization, and immuNohistochemistry,” Clinical Cancer Research, Vol. 9, No. 10, 2003, pp. 3645-3652.

[74]   F. Cappuzzo, M. Varella-Garcia, H. Shigematsu, I. Domenichini, S. Bartolini, G. L. Ceresoli, E. Rossi, V. Ludovini, V. Gregorc, L. Toschi, W. A. Franklin, L. Crino, A. F. Gazdar, P. A. Bunn Jr. and F. R. Hirsch, “Increased HER2 Gene Copy Number Is Associated with Response to Gefitinib Therapy in Epidermal Growth Factor Receptor-Positive Non-Small-Cell Lung Cancer Patients,” Journal of Clinical Oncology, Vol. 23, No. 22, 2005, pp. 5007-5018. Doi:10.1200/JCO.2005.09.111

[75]   R. S. Herbst and D. M. Shin, “Monoclonal Antibodies to Target Epidermal Growth Factor Receptor-Positive Tumors: A New Paradigm for Cancer Therapy,” Cancer, Vol. 94, No. 5, 2002, pp. 1593-1611. Doi:10.1002/cncr.10372

[76]   J. Baselga, D. Pfister, M. R. Cooper, R. Cohen, B. Burtness, M. Bos, G. D’Andrea, A. Seidman, L. Norton, K. Gunnett, J. Falcey, V. Anderson, H. Waksal and J. Mendelsohn, “Phase I Studies of Anti-Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination with Cisplatin,” Journal of Clinical Oncology, Vol. 18, No. 4, 2000, pp. 904-914.

[77]   C. D. Thienelt, P. A. Bunn Jr., N. Hanna, A. Rosenberg, M. N. Needle, M. E. Long, D. L. Gustafson and K. Kelly, “Multicenter Phase I/II Study of Cetuximab with Paclitaxel and Carboplatin in Untreated Patients with Stage IV Non-Small-Cell Lung Cancer,” Journal of Clinical Oncology, Vol. 23, No. 34, 2005, pp. 8786-8793. Doi:10.1200/JCO.2005.03.1997

[78]   C. A. Butts, D. Bodkin, E. L. Middleman, C. W. Englund, D. Ellison, Y. Alam, H. Kreisman, P. Graze, J. Maher, H. J. Ross, P. M. Ellis, W. McNulty, E. Kaplan, V. Pautret, M. R. Weber and F. A. Shepherd, “Randomized Phase II Study of Gemcitabine plus Cisplatin or Carboplatin [Corrected], with or without Cetuximab, as First-Line Therapy for Patients with Advanced or Metastatic Non Small-Cell Lung Cancer,” Journal of Clinical Oncology, Vol. 25, No. 36, 2007, pp. 5777-5784. Doi:10.1200/JCO.2007.13.0856

[79]   H. Borghaei, C. J. Langer, M. Millenson, K. J. Ruth, S. Litwin, H. Tuttle, J. S. Seldomridge, M. Rovito, D. Mintzer, R. Cohen and J. Treat, “Phase II Study of Paclitaxel, Carboplatin, and Cetuximab as First Line Treatment, for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): Results of OPN-017,” Journal of Thoracic Oncology, Vol. 3, No. 11, 2008, pp. 1286-1292. Doi:10.1097/JTO.0b013e318189f50e

[80]   R. Rosell, G. Robinet, A. Szczesna, R. Ramlau, M. Constenla, B. C. Mennecier, W. Pfeifer, K. J. O’Byrne, T. Welte, R. Kolb, R. Pirker, A. Chemaissani, M. Perol, M. R. Ranson, P. A. Ellis, K. Pilz and M. Reck, “Randomized Phase II Study of Cetuximab plus Cisplatin/Vinorelbine Compared with Cisplatin/Vinorelbine Alone as First-Line Therapy in EGFR-Expressing Advanced Non-Small-Cell Lung Cancer,” Annals of Oncology, Vol. 19, No. 2, 2008, pp. 362-369. Doi:10.1093/annonc/mdm474

[81]   R. S. Herbst, K. Kelly, K. Chansky, P. C. Mack, W. A. Franklin, F. R. Hirsch, J. N. Atkins, S. R. Dakhil, K. S. Albain, E. S. Kim, M. Redman, J. J. Crowley and D. R. Gandara, “Phase II Selection Design Trial of Concurrent Chemotherapy and Cetuximab versus Chemotherapy Followed by Cetuximab in Advanced-Stage Non-Small-Cell Lung Cancer: Southwest Oncology Group Study S0342,” Journal of Clinical Oncology, Vol. 28, No. 31, 2010, pp. 4747-4754. Doi:10.1200/JCO.2009.27.9356

[82]   C. Gridelli, A. Morabito, V. Gebbia, M. Mencoboni, R. Mattioli, M. R. Valerio, G. Valmadre, P. Maione, A. Rossi, T. Cascone, F. Morgillo, M. Di Maio, M. C. Piccirillo, C. Gallo, F. Perrone and F. Ciardiello, “Cetuximab and Gemcitabine in Elderly or Adult PS2 Patients with Advanced Non-Small-Cell Lung Cancer: The Cetuximab in Advanced Lung Cancer (CALC1-E and CALC1-PS2) Randomized Phase II Trials,” Lung Cancer, Vol. 67, No. 1, 2010, pp. 86-92. Doi:10.1016/j.lungcan.2009.03.021

[83]   D. R. Spigel, F. A. Greco, D. S. Thompson, C. Webb, J. Rubinsak, R. C. Inhorn, J. Reeves Jr., E. R. Vazquez, C. M. Lane, H. A. Burris III and J. D. Hainsworth, “Phase II Study of Cetuximab, Docetaxel, and Gemcitabine in Patients with Previously Untreated Advanced Non-Small-Cell Lung Cancer,” Clinical Lung Cancer, Vol. 11, No. 3, 2010, pp. 198-203. Doi:10.3816/CLC.2010.n.026

[84]   Y. Cao, C. Liao, A. Tan, L. Liu and F. Gao, “Meta-Analysis of Incidence and Risk of Hypomagnesemia with Cetuximab for Advanced Cancer,” Chemotherapy, Vol. 56, No. 6, 2010, pp. 459-465. Doi:10.1159/000321011

[85]   R. Pirker, J. R. Pereira, A. Szczesna, J. von Pawel, M. Krzakowski, R. Ramlau, I. Vynnychenko, K. Park, C.-T. Yu, V. Ganul, J.-K. Roh, E. Bajetta, K. O’Byrne, F. de Marinis, W. Eberhardt, T. Goddemeier, M. Emig and U. Gatzemeier, “Cetuximab plus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer (FLEX): An Open-Label Randomised Phase III Trial,” Lancet, Vol. 373, No. 9674, 2009, pp. 1525-1531. Doi:10.1016/S0140-6736(09)60569-9

[86]   T. J. Lynch, T. Patel, L. Dreisbach, M. McCleod, W. J. Heim, R. C. Hermann, E. Paschold, N. O. Iannotti, S. Dakhil, S. Gorton, V. Pautret, M. R. Weber and D. Woytowitz, “Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non-Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099,” Journal of Clinical Oncology, Vol. 28, No. 6, 2010, pp. 911-917. Doi:10.1200/JCO.2009.21.9618

[87]   S. Huang, E. A. Armstrong, S. Benavente, P. Chinnaiyan and P. M. Harari, “Dual-Agent Molecular Targeting of the Epidermal Growth Factor Receptor (EGFR): Combining Anti-EGFR Antibody with Tyrosine Kinase Inhibitor,” Cancer Research, Vol. 64, No. 15, 2004, pp. 5355-5362. Doi:10.1158/0008-5472.CAN-04-0562

[88]   T. Cascone, M. P. Morelli, F. Morgillo, W.-Y. Kim, G. Rodolico, S. Pepe, G. Tortora, L. Berrino, H.-Y. Lee, J. V. Heymach and F. Ciardiello, “Synergistic Anti-Proliferative and Pro-Apoptotic Activity of Combined Therapy with Bortezomib, a Proteasome Inhibitor, with Anti-Epidermal Growth Factor Receptor (EGFR) Drugs in Human Cancer Cells,” Journal of Cellular Physiology, Vol. 216, No. 3, 2008, pp. 698-707. Doi:10.1002/jcp.21444

[89]   P. Matar, F. Rojo, R. Cassia, G. Moreno-Bueno, S. Di Cosimo, J. Tabernero, M. Guzmán, S. Rodriguez, J. Arribas, J. Palacios and J. Baselga, “Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225): Superiority over Single-Agent Receptor Targeting,” Clinical Cancer Research, Vol. 10, No. 19, 2004, pp. 6487-6501. Doi:10.1158/1078-0432.CCR-04-0870

[90]   A. Z. Dudek, K. Lesniewski-Kmak, N. J. Shehadeh, O. N. Pandey, M. Franklin, R. A. Kratzke, E. W. Greeno and P. Kumar, “Phase I Study of Bortezomib and Cetuximab in Patients with solid tumours expressing epidermal growth factor receptor,” British Journal of Cancer, Vol. 100, No. 9, 2009, pp. 1379-1384. Doi:10.1038/sj.bjc.6605043

[91]   M. J. Guarino, C. J. Schneider, M. A. Hosford, J. R. Brahmer, C. M. Rudin, F. G. Finckenstein, R. E. Philip-Norton, H. Lu, M. R. Weber and D. S. Ettinger, “Dual Inhibition of the Epidermal Growth Factor Receptor Pathway with Cetuximab and Erlotinib: A Phase I Study in Patients with Advanced Solid Malignancies,” Oncologist, Vol. 14, No. 2, 2009, pp. 119-124. Doi:10.1634/theoncologist.2008-0124

[92]   S. Ramalingam, J. Forster, C. Naret, T. Evans, M. Sulecki, H. Lu, P. Teegarden, M. R. Weber and C. P. Belani, “Dual Inhibition of the Epidermal Growth Factor Receptor with Cetuximab, an IgG1 Monoclonal Antibody, and Gefitinib, a Tyrosine Kinase Inhibitor, in Patients with Refractory Non-Small Cell Lung Cancer (NSCLC): A Phase I Study,” Journal of Thoracic Oncology, Vol. 3, No. 3, 2008, pp. 258-264. Doi:10.1097/JTO.0b013e3181653d1b

[93]   J. W. Neal, R. S. Heist, P. Fidias, J. S. Temel, M. Huberman, J. P. Marcoux, A. Muzikansky, T. J. Lynch and L. V. Sequist, “Cetuximab Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer after Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy,” Journal of Thoracic Oncology, Vol. 5, No. 11, 2010, pp. 1855-1858. Doi:10.1097/JTO.0b013e3181f0bee0

[94]   “Chemotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis Using Updated Data on Individual Patients from 52 Randomised Clinical Trials. Non-Small Cell Lung Cancer Collaborative Group,” BMJ, Vol. 311, No. 7010, 1995, pp. 899-909. Doi:10.1136/bmj.311.7010.899

[95]   J. A. Bonner, P. M. Harari, J. Giralt, N. Azarnia, D. M. Shin, R. B. Cohen, C. U. Jones, R. Sur, D. Raben, J. Jassem, R. Ove, M. S. Kies, J. Baselga, H. Youssoufian, N. Amellal, E. K. Rowinsky and K. K. Ang, “Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck,” New England Journal of Medicine, Vol. 354, No. 6, 2006, pp. 567-578. Doi:10.1056/NEJMoa053422

[96]   S. Hughes, J. Liong, A. Miah, S. Ahmad, M. Leslie, P. Harper, J. Prendiville, J. Shamash, R. Subramaniam, A. Gaya, J. Spicer and D. Landau, “A Brief Report on the Safety Study of Induction Chemotherapy Followed by Synchronous Radiotherapy and Cetuximab in Stage III Non-Small Cell Lung Cancer (NSCLC): SCRATCH Study,” Journal of Thoracic Oncology, Vol. 3, No. 6, 2008, pp. 648-651. Doi:10.1097/JTO.0b013e3181757a60

[97]   National Cancer Institute (NCI), North Central Cancer Treatment Group, Cancer and Leukemia Group B, “High-Dose Or Standard-Dose Radiation Therapy and Chemotherapy with or without Cetuximab in Treating Patients with Newly Diagnosed Stage iii Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery,” National Library of Medicine (US). ClinicalTrials.gov., Bethesda, 2000. http://clinicaltrials.gov/show/NCT00533949NLMIdentifier: NCT00533949

[98]   A. Jatoi, S. E. Schild, N. Foster, G. T. Henning, K. J. Dornfeld, P. J. Flynn, T. R. Fitch, S. R. Dakhil, K. M. Rowland, P. J. Stella, G. S. Soori and A. Adjei, “A Phase II Study of Cetuximab and Radiation in Elderly and/or Poor Performance Status Patients with Locally Advanced Non-Small-Cell Lung Cancer (N0422),” Annals of Oncology, Vol. 21, No. 10, 2010, pp. 2040-2044. Doi:10.1093/annonc/mdq075

[99]   A. Hallqvist, G. Wagenius, H. Rylander, O. Brodin, E. Holmberg, B. Lodén, S.-B. Ewers, S. Bergstrom, G. Wichardt-Johansson, K. Nilsson, L. Ekberg, C. Sederholm and J. Nyman, “Concurrent Cetuximab and Radiotherapy after Docetaxel-Cisplatin Induction Chemotherapy in Stage III NSCLC: Satellite—A Phase II Study from the Swedish Lung Cancer Study Group,” Lung Cancer, Vol. 71, No. 2, 2011, pp. 166-172. Doi:10.1016/j.lungcan.2010.05.011

[100]   A. D. Jensen, M. W. Münter, H. Bischoff, R. Haselmann, C. Timke, R. Krempien, F. Sterzing, S. Nill, S. Heeger, A. Hoess, U. Haberkorn, P. E. Huber, M. Steins, M. Thomas, J. Debus and K. K. Herfarth, “Treatment of Non-Small Cell Lung Cancer with Intensity-Modulated Radiation Therapy in Combination with Cetuximab: The NEAR Protocol (NCT00115518),” BMC Cancer, Vol. 6, 2006, p. 122. Doi:10.1186/1471-2407-6-122

[101]   G. R. Blumenschein Jr., R. Paulus, W. J. Curran, F. Robert, F. Fossella, M. Werner-Wasik, R. S. Herbst, P. O. Doescher, H. Choy and R. Komaki, “Phase II Study of Cetuximab in Combination with Chemoradiation in Patients with Stage IIIA/B Non-Small-Cell Lung Cancer: RTOG 0324,” Journal of Clinical Oncology, Vol. 29, No. 17, 2011, pp. 2312-2318. Doi:10.1200/JCO.2010.31.7875

[102]   R. Govindan, J. Bogart, T. Stinchcombe, X. Wang, L. Hodgson, R. Kratzke, J. Garst, T. Brotherton and E. E. Vokes, “Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407,” Journal of Clinical Oncology, Vol. 29, No. 23, 2011, pp. 3120-3125. Doi:10.1200/JCO.2010.33.4979

[103]   A. Maillet, L. Guilleminault, E. Lemarié, S. Lerondel, N. Azzopardi, J. Montharu, N. Congy-Jolivet, P. Reverdiau, B. Legrain, C. Parent, D.-H. Douvin, J. Hureaux, Y. Courty, M. De Monte, P. Diot, G. Paintaud, A. Le Pape, H. Watier and N. Heuzé-Vourc’h, “The Airways, a Novel Route for Delivering Monoclonal Antibodies to Treat Lung Tumors,” Pharmaceutical Research, Vol. 28, No. 9, 2011, pp. 2147-2156. Doi:10.1007/s11095-011-0442-5

[104]   C. J. Allegra, J. M. Jessup, M. R. Somerfield, S. R. Hamilton, E. H. Hammond, D. F. Hayes, P. K. McAllister, R. F. Morton and R. L. Schilsky, “American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients with Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy,” Journal of Clinical Oncology, Vol. 27, No. 12, 2009, pp. 2091-2096. Doi:10.1200/JCO.2009.21.9170

[105]   S. Khambata-Ford, C. T. Harbison, L. L. Hart, M. Awad, L.-A. Xu, C. E. Horak, S. Dakhil, R. C. Hermann, T. J. Lynch and M. R. Weber, “Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non-Small-Cell Lung Cancer,” Journal of Clinical Oncology, Vol. 28, No. 6, 2010, pp. 918-927. Doi:10.1200/JCO.2009.25.2890

[106]   R. Pirker, J. R. Pereira, J. von Pawel, M. Krzakowski, R. Ramlau, K. Park, F. de Marinis, W. E. E. Eberhardt, L. Paz-Ares, S. St?rkel, K.-M. Schumacher, A. von Heydebreck, I. Celik and K. J. O’Byrne, “EGFR Expression as a Predictor of Survival for First-Line Chemotherapy plus Cetuximab in Patients with Advanced Non-Small-Cell Lung Cancer: Analysis of Data from the Phase 3 FLEX Study,” Lancet Oncology, Vol. 13, No. 1, 2012, pp. 33-42. Doi:10.1016/S1470-2045(11)70318-7

[107]   U. Gatzemeier, J. von Pawel, I. Vynnychenko, P. Zatloukal, F. de Marinis, W. E. E. Eberhardt, L. Paz-Ares, K.-M. Schumacher, T. Goddemeier, K. J. O’Byrne and R. Pirker, “First-Cycle Rash and Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Cetuximab in Combination with First-Line Chemotherapy: A Subgroup Analysis of Data from the FLEX Phase 3 Study,” Lancet Oncology, Vol. 12, No. 1, 2011, pp. 30-37. Doi:10.1016/S1470-2045(10)70278-3

[108]   M. A. Socinski, “Antibodies to the Epidermal Growth Factor Receptor in Non Small Cell Lung Cancer: Current Status of Matuzumab and Panitumumab,” Clinical Cancer Research, Vol. 13, No. 15, 2007, pp. s4597-s4601. Doi:10.1158/1078-0432.CCR-07-0335

[109]   U. Vanhoefer, M. Tewes, F. Rojo, O. Dirsch, N. Schleucher, O. Rosen, J. Tillner, A. Kovar, A. H. Braun, T. Trarbach, S. Seeber, A. Harstrick and J. Baselga, “Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients with Advanced Solid Tumors That Express the Epidermal Growth Factor Receptor,” Journal of Clinical Oncology, Vol. 22, No. 1, 2004, pp. 175-184. Doi:10.1200/JCO.2004.05.114

[110]   M. M. Schittenhelm, C. Kollmannsberger, K. Oechsle, A. Harlow, J. Morich, F. Honecker, R. Kurek, S. St?rkel, L. Kanz, C. L. Corless, K.-K. Wong, C. Bokemeyer and M. C. Heinrich, “Molecular Determinants of Response to Matuzumab in Combination with Paclitaxel for Patients with Advanced Non-Small Cell Lung Cancer,” Molecular Cancer Therapeutics, Vol. 8, No. 3, 2009, pp. 481-489. Doi:10.1158/1535-7163.MCT-08-1068

[111]   J. H. Schiller, J. von Pawel, P. Schütt, R. H. Ansari, M. Thomas, M. Saleh, R. D. McCroskey, W. Pfeifer, T. A. Marsland, G. H. Kloecker, M. Sebastian, R. Pirker, R. Kurek, C. Beadman and M. A. Socinski, “Pemetrexed with or without Matuzumab as Second-Line Treatment for Patients with Stage IIIB/IV Non-Small Cell Lung Cancer,” Journal of Thoracic Oncology, Vol. 5, No. 12, 2010, pp. 1977-1985. Doi:10.1097/JTO.0b013e3181f4a5c9

[112]   C. Mateo, E. Moreno, K. Amour, J. Lombardero, W. Harris and R. Pérez, “Humanization of a Mouse Monoclonal Antibody That Blocks the Epidermal Growth Factor Receptor: Recovery of Antagonistic Activity,” Immunotechnology, Vol. 3, No. 1, 1997, pp. 71-81. Doi:10.1016/S1380-2933(97)00065-1

[113]   G. Bebb, C. Smith, S. Rorke, W. Boland, L. Nicacio, R. Sukhoo and A. Brade, “Phase I Clinical Trial of the Anti-EGFR Monoclonal Antibody Nimotuzumab with Concurrent External Thoracic Radiotherapy in Canadian Patients Diagnosed with Stage IIb, III or IV Non-Small Cell Lung Cancer Unsuitable for Radical Therapy,” Cancer Chemotherapy and Pharmacology, Vol. 67, No. 4, 2011, pp. 837-845. Doi:10.1007/s00280-010-1379-9

[114]   H. J. Choi, J. H. Sohn, C. G. Lee, H. S. Shim, I.-J. Lee, W. I. Yang, J. E. Kwon, S. K. Kim, M.-S. Park, J. H. Lee and J. H. Kim, “A Phase I Study of Nimotuzumab in Combination with Radiotherapy in Stages IIB-IV Non-Small Cell Lung Cancer Unsuitable for Radical Therapy: Korean Results,” Lung Cancer, Vol. 71, No. 1, 2011, pp. 55-59. Doi:10.1016/j.lungcan.2010.04.010

[115]   B. C. Cho, Yonsei University, “Phase II Study of Gefitinib plus Nimotuzumab versus Gefitinib in Non-Small Cell Lung Cancer (DATE)” National Library of Medicine (US), ClinicalTrials.gov, Bethesda, 2000. http://clinicaltrials.gov/show/NCT01498562 NLM Identifier: NCT01498562

[116]   Biotech Pharmaceutical Co., Ltd. Yanzhao, Tianjin Medical University Cancer Institute and Hospital, “Nimotuzumab in Combination with Paclitaxel Liposome and Carboplatin (TP Regimen) for the Advanced NSCLC Patients,” National Library of Medicine (US), Clinical-Trials.gov, Bethesda, 2000. http://clinicaltrials.gov/show/NCT01393080 NLM Identifier: NCT01393080

[117]   J. V. Heymach, M. Nilsson, G. Blumenschein, V. Papadimitrakopoulou and R. Herbst, “Epidermal Growth Factor Receptor Inhibitors in Development for the Treatment of Non-Small Cell Lung Cancer,” Clinical Cancer Research, Vol. 12, No. 14, 2006, pp. 4441s-4445s. Doi:10.1158/1078-0432.CCR-06-0286

[118]   L. M. Weiner, A. S. Belldegrun, J. Crawford, A. W. Tolcher, P. Lockbaum, R. H. Arends, L. Navale, R. G. Amado, G. Schwab and R. A. Figlin, “Dose and Schedule Study of Panitumumab Monotherapy in Patients with Advanced Solid Malignancies,” Clinical Cancer Research, Vol. 14, No. 2, 2008, pp. 502-508. Doi:10.1158/1078-0432.CCR-07-1509

[119]   G. R. Blumenschein Jr., K. Reckamp, G. J. Stephenson, T. O’Rourke, G. Gladish, J. McGreivy, Y.-N. Sun, Y. Ye, M. Parson and A. Sandler, “Phase 1b Study of Motesanib, an Oral Angiogenesis Inhibitor, in Combination with Carboplatin/Paclitaxel and/or Panitumumab for the Treatment of Advanced Non-Small Cell Lung Cancer,” Clinical Cancer Research, Vol. 16, No. 1, 2010, pp. 279-290. Doi:10.1158/1078-0432.CCR-09-1675

[120]   National Cancer Institute (NCI), “Chemotherapy and Radiation Therapy with or without Panitumumab in Treating Patients with Stage IIIA Non-Small Cell Lung Cancer,” National Library of Medicine (US), ClinicalTrials.gov, Bethesda, 2000. http://clinicaltrials.gov/show/NCT00979212NLMIdentifier NCT00979212

[121]   Vejle Hospital, “First-Line Chemotherapy and Panitumumab in Advanced Non-Small Cell Lung Cancer (Lung-TRIO),” National Library of Medicine (US), ClinicalTrials.gov, Bethesda, 2000. http://clinicaltrials.gov/show/NCT01038037NLMIdentifier NCT01038037

[122]   Gesellschaft fur Medizinische Innovation—Hamatologie und Onkologie mbH. WiSP Wissenschaftlicher Service Pharma GmbH, “Panitumumab plus Pemetrexed and Cisplatin (PemCisP) versus PemCis in the First-Line Treatment of Patients with Non-Small Cell Lung Cancer,” National Library of Medicine (US), ClinicalTrials.gov, Bethesda, 2000. http://clinicaltrials.gov/show/NCT01088620NLMIdentifier NCT01088620

[123]   B. Kuenen, P. O. Witteveen, R. Ruijter, G. Giaccone, A. Dontabhaktuni, F. Fox, T. Katz, H. Youssoufian, J. Zhu, E. K. Rowinsky and E. E. Voest, “A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed against EGFR in Patients with Advanced Solid Malignancies,”Clinical Cancer Research, Vol. 16, No. 6, 2010, pp. 1915-1923. Doi:10.1158/1078-0432.CCR-09-2425

[124]   ImClone LLC, Parexel, “First-Line Treatment of Participants with Stage IV Squamous Non-Small Cell Lung Cancer with Necitumumab and Gemcitabine-Cisplatin (SQUIRE),” National Library of Medicine (US), ClinicalTrials.gov, Bethesda, 2000. http://clinicaltrials.gov/show/NCT00981058 NLM Identifier NCT00981058

[125]   Parexel. PPD, Medidata Solutions, Laboratory Corporation of America, University of Colorado, Denver, Thermo Fisher Scientific, ImClone LLC., “First-Line Treatment of Patients with Stage iv Nonsquamous Non-Small Cell Lung Cancer with Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin (INSPIRE),” National Library of Medicine (US), ClinicalTrials.gov, Bethesda, 2000. http://clinicaltrials.gov/show/NCT00982111 NLM Identifier: NCT00982111

[126]   Lilly, “Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab,” Bristol-Myers Squibb, Princeton, 2011. http://www.bms.com/news/press_releases/pages/default.aspx?RSSLink=http://www.businesswire.com/news/bms/20110202006011/en&t=634322838509124725).

[127]   M. M. Goldenberg, “Trastuzumab, a Recombinant DNA-Derived Humanized Monoclonal Antibody, a Novel Agent for the Treatment of Metastatic Breast Cancer,” Clinical Therapeutics, Vol. 21, No. 2, 1999, pp. 309-318. Doi:10.1016/S0149-2918(00)88288-0

[128]   F. R. Hirsch, B. Helfrich, W. A. Franklin, M. Varella-Garcia, D. C. Chan and P. A. Bunn Jr., “Preclinical Studies of Gemcitabine and Trastuzumab in Breast and Lung Cancer Cell Lines,” Clinical Breast Cancer, Vol. 3, Suppl 1, 2002, pp. 12-16. Doi:10.3816/CBC.2002.s.003

[129]   P. N. Lara Jr., L. Laptalo, J. Longmate, D. H. M. Lau, R. Gandour-Edwards, P. H. Gumerlock, J. H. Doroshow and D. R. Gandara, “Trastuzumab plus Docetaxel in HER2/ Neu-Positive Non-Small-Cell Lung Cancer: A California Cancer Consortium Screening and Phase II Trial,” Clinical Lung Cancer, Vol. 5, No. 4, 2004, pp. 231-236. Doi:10.3816/CLC.2004.n.004

[130]   G. Clamon, J. Herndon, J. Kern, R. Govindan, J. Garst, D. Watson and M. Green, “Lack of Trastuzumab Activity in Nonsmall Cell Lung Carcinoma with Overexpression of erb-B2: 39810: A Phase II Trial of Cancer and Leukemia Group B,” Cancer, Vol. 103, No. 8, 2005, pp. 1670-1675. Doi:10.1002/cncr.20950

[131]   C. J. Langer, P. Stephenson, A. Thor, M. Vangel and D. H. Johnson, “Trastuzumab in the Treatment of Advanced Non-Small-Cell Lung Cancer: Is There a Role? Focus on Eastern Cooperative Oncology Group Study 2598,” Journal of Clinical Oncology, Vol. 22, No. 7, 2004, pp. 1180-1187. Doi:10.1200/JCO.2004.04.105

[132]   R. G. Zinner, B. S. Glisson, H. T. Tran, Y. Yang, T. L. Smith, R. D. Mass and R. S. Herbst, “Trastuzumab in Combination with Cisplatin and Gemcitabine in Patients with Her2-Overexpressing, Untreated, Advanced Non-Small Cell Lung Cancer: Report of a Phase II Trial and Findings Regarding Optimal Identification of Patients with Her2-Overexpressing Disease,” Lung Cancer, Vol. 44, No. 1, 2004, pp. 99-110. Doi:10.1016/j.lungcan.2003.09.026

[133]   U. Gatzemeier, G. Groth, C. Butts, N. Van Zandwijk, F. Shepherd, A. Ardizzoni, C. Barton, P. Ghahramani and V. Hirsh, “Randomized Phase II Trial of Gemcitabine-Cisplatin with or without Trastuzumab in HER2-Positive Non-Small-Cell Lung Cancer,” Annals of Oncology, Vol. 15, No. 1, 2004, pp. 19-27. Doi:10.1093/annonc/mdh031

[134]   M. C. Franklin, K. D. Carey, F. F. Vajdos, D. J. Leahy, A. M. de Vos and M. X. Sliwkowski, “Insights into ErbB Signaling from the Structure of the ErbB2-Pertuzumab Complex,” Cancer Cell, Vol. 5, No. 4, 2004, pp. 317-328. Doi:10.1016/S1535-6108(04)00083-2

[135]   K. Sakai, H. Yokote, K. Murakami-Murofushi, T. Tamura, N. Saijo and K. Nishio, “Pertuzumab, a Novel HER Dimerization Inhibitor, Inhibits the Growth of Human Lung Cancer Cells Mediated by the HER3 Signaling Pathway,” Cancer Science, Vol. 98, No. 9, 2007, pp. 1498-1503. Doi:10.1111/j.1349-7006.2007.00553.x

[136]   R. S. Herbst, A. M. Davies, R. B. Natale, T. P. Dang, J. H. Schiller, L. L. Garland, V. A. Miller, D. Mendelson, A. D. Van den Abbeele, Y. Melenevsky, D. J. de Vries, D. A. Eberhard, B. Lyons, S. G. Lutzker and B. E. Johnson, “Efficacy and Safety of Single-Agent Pertuzumab, a Human Epidermal Receptor Dimerization Inhibitor, in Patients with Non Small Cell Lung Cancer,” Clinical Cancer Research, Vol. 13, No. 20, 2007, pp. 6175-6181. Doi:10.1158/1078-0432.CCR-07-0460

[137]   A. G. Roche Pharma and A. Genentech, “Study of the Combination of Erlotinib and Pertuzumab in Patients with Relapsed Non-Small Cell Lung Cancer (PENGUIN),” National Library of Medicine (US), ClinicalTrials.gov, Bethesda, 2000. http://clinicaltrials.gov/show/NCT00855894 NLM Identifier: NCT00855894

[138]   S. L. Topalian, G. J. Weiner and D. M. Pardoll, “Cancer Immunotherapy Comes of Age,” Journal of Clinical Oncology, Vol. 29, No. 36, 2011, pp. 4828-4836. Doi:10.1200/JCO.2011.38.0899

[139]   S. G. Holtan and D. J. Creedon, “Mother Knows Best: Lessons from Fetomaternal Tolerance Applied to Cancer Immunity,” Frontiers in Bioscience, Vol. 3, 2011, pp. 1533-1540. Doi:10.2741/243

[140]   I. Mellman, G. Coukos and G. Dranoff, “Cancer Immunotherapy Comes of Age,” Nature, Vol. 480, No. 7378, 2011, pp. 480-489. Doi:10.1038/nature10673

[141]   L. H. Camacho, “Novel Therapies Targeting the Immune System: CTLA4 Blockade with Tremelimumab (CP-675,206), a Fully Human Monoclonal Antibody,” Expert Opinion on Investigational Drugs, Vol. 17, No. 3, 2008, pp. 371-385. Doi:10.1517/13543784.17.3.371

[142]   H. Dong, S. E. Strome, D. R. Salomao, H. Tamura, F. Hirano, D. B. Flies, P. C. Roche, J. Lu, G. Zhu, K. Tamada, V. A. Lennon, E. Celis and L. Chen, “Tumor-Associated B7-H1 Promotes T-Cell Apoptosis: A Potential Mechanism of Immune Evasion,” Nature Medicine, Vol. 8, No. 8, 2002, pp. 793-800.

[143]   J. Konishi, K. Yamazaki, M. Azuma, I. Kinoshita, H. Dosaka-Akita and M. Nishimura, “B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression,” Clinical Cancer Research, Vol. 10, No. 15, 2004, pp. 5094-5100. Doi:10.1158/1078-0432.CCR-04-0428

[144]   T. J. Lynch, I. Bondarenko, A. Luft, P. Serwatowski, F. Barlesi, R. Chacko, M. Sebastian, J. Neal, H. Lu, J.-M. Cuillerot and M. Reck, “Ipilimumab in Combination with Paclitaxel and Carboplatin as First-Line Treatment in Stage IIIB/IV Non-Small-Cell Lung Cancer: Results from a Randomized, Double-Blind, Multicenter Phase II Study,” Journal of Clinical Oncology, Vol. 30, No. 17, 2012, pp. 2046-2054. Doi:10.1200/JCO.2011.38.4032

[145]   B.-M. Squibb, “Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab plus Paclitaxel and Carboplatin versus Placebo Plus Paclitaxel and Carboplatin,” National Library of Medicine (US), Clinical-Trials.gov, Bethesda, 2000. http://clinicaltrials.gov/show/NCT01285609 NLM Identifier NCT01285609

[146]   Pfizer, “Randomized Study of CP-675,206 or Best Supportive Care Immediately after Platinum-Based Therapy for Non-Small Cell Lung Cancer (NSCLC),” National Library of Medicine (US), ClinicalTrials.gov, Bethesda, 2000. http://clinicaltrials.gov/show/NCT00312975NLMIdentifier NCT00312975

[147]   J. R. Brahmer, C. G. Drake, I. Wollner, J. D. Powderly, J. Picus, W. H. Sharfman, E. Stankevich, A. Pons, T. M. Salay, T. L. McMiller, M. M. Gilson, C. Wang, M. Selby, J. M. Taube, R. Anders, L. Chen, A. J. Korman, D. M. Pardoll, I. Lowy and S. L. Topalian, “Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates,” Journal of Clinical Oncology, Vol. 28, No. 19, 2010, pp. 3167-3175. Doi:10.1200/JCO.2

[148]   S. L. Topalian, F. S. Hodi, P. D. Leming, D. R. Spigel, S. J. Antonia, L. Horn, C. G. Drake, D. M. Pardoll, L. Chen, W. H. Sharfman, R. A. Anders, J. M. Taube, T. L. McMiller, H. Xu, A. J. Korman, M. Jure-Kunkel, S. Agrawal, D. McDonald, G. D. Kollia, A. Gupta, J. M. Wigginton and M. Sznol, “Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer,” New England Journal of Medicine, Vol. 366, No. 26, 2012, pp. 2443-2454. Doi:10.1056/NEJMoa1200690

[149]   J. R. Brahmer, S. S. Tykodi, L. Q. M. Chow, W.-J. Hwu, S. L. Topalian, P. Hwu, C. G. Drake, L. H. Camacho, J. Kauh, K. Odunsi, H. C. Pitot, O. Hamid, S. Bhatia, R. Martins, K. Eaton, S. Chen, T. M. Salay, S. Alaparthy, J. F. Grosso, A. J. Korman, S. M. Parker, S. Agrawal, S. M. Goldberg, D. M. Pardoll, A. Gupta and J. M. Wigginton, “Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer,” New England Journal of Medicine, Vol. 366, No. 26, 2012, pp. 2455-2465. Doi:10.1056/NEJMoa1200694

[150]   G. Fürstenberger and H.-J. Senn, “Insulin-Like Growth Factors and Cancer,” Lancet Oncology, Vol. 3, No. 5, 2002, pp. 298-302. Doi:10.1016/S1470-2045(02)00731-3

[151]   H. Yu, M. R. Spitz, J. Mistry, J. Gu, W. K. Hong and X. Wu, “Plasma Levels of Insulin-Like Growth Factor-I and Lung Cancer Risk: A Case-Control Analysis,” Journal of the National Cancer Institute, Vol. 91, No. 2, 1999, pp. 151-156. Doi:10.1093/jnci/91.2.151

[152]   F. Morgillo, W.-Y. Kim, E. S. Kim, F. Ciardiello, W. K. Hong and H.-Y. Lee, “Implication of the Insulin-Like Growth Factor-IR Pathway in the Resistance of Non-Small Cell Lung Cancer Cells to Treatment with Gefitinib,” Clinical Cancer Research, Vol. 13, No. 9, 2007, pp. 2795-2803. Doi:10.1158/1078-0432.CCR-06-2077

[153]   M. Nakagawa, H. Uramoto, S. Oka, Y. Chikaishi, T. Iwanami, H. Shimokawa, T. So, T. Hanagiri and F. Tanaka, “Clinical Significance of IGF1R Expression in Non-Small-Cell Lung Cancer,” Clinical Lung Cancer, Vol. 13, No. 2, 2012, pp. 136-142. Doi:10.1016/j.cllc.2011.10.006

[154]   L. R. Molife, P. C. Fong, V. Karavasilis, T. A. Yap, D. Olmos, J. Spicer, S. Postel-Vinay, D. Yin, A. Lipton, L. Demers, K. Leitzel, A. Gualberto and J. S. de Bono, “The Insulin-Like Growth Factor-I Receptor Inhibitor Figitumumab (CP-751,871) in Combination with Docetaxel in Patients with Advanced Solid Tumours: Results of a Phase Ib Dose-Escalation, Open-Label Study,” British Journal of Cancer, Vol. 103, No. 3, 2010, pp. 332-339. Doi:10.1038/sj.bjc.6605767

[155]   D. D. Karp, L. G. Paz-Ares, S. Novello, P. Haluska, L. Garland, F. Cardenal, L. J. Blakely, P. D. Eisenberg, C. J. Langer, G. Blumenschein Jr., F. M. Johnson, S. Green and A. Gualberto, “Phase II Study of the Anti-Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination with Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non-Small-Cell Lung Cancer,” Journal of Clinical Oncology, Vol. 27, No. 15, 2009, pp. 2516-2522. Doi:10.1200/JCO.2008.19.9331

[156]   D. D. Karp, M. N. Pollak, R. B. Cohen, P. D. Eisenberg, P. Haluska, D. Yin, A. Lipton, L. Demers, K. Leitzel, M. L. Hixon, L. W. Terstappen, L. Garland, L. G. Paz-Ares, F. Cardenal, C. J. Langer and A. Gualberto, “Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751,871) in Combination with Paclitaxel and Carboplatin,” Journal of Thoracic Oncology, Vol. 4, No. 11, 2009, pp. 1397-1403. Doi:10.1097/JTO.0b013e3181ba2f1d

[157]   A. Gualberto, M. L. Hixon, D. D. Karp, D. Li, S. Green, M. Dolled-Filhart, L. G. Paz-Ares, S. Novello, J. Blakely, C. J. Langer and M. N. Pollak, “Pre-Treatment Levels of Circulating Free IGF-1 Identify NSCLC Patients Who Derive Clinical Benefit from Figitumumab,” British Journal of Cancer, Vol. 104, No. 1, 2011, pp. 68-74. Doi:10.1038/sj.bjc.6605972

[158]   Pfizer, “Carboplatin and Paclitaxel with or without CP-751, 871 (an IGF-1R inhibitor) for Advanced NSCLC of Squamous, Large Cell and Adenosquamous Carcinoma Histology,” National Library of Medicine (US), Clinical-Trials.gov, Bethesda, 2000. http://clinicaltrials.gov/show/NCT00596830 NLM Identifier: NCT00596830

[159]   http://www.ascopost.com/articles/november-2010/figitumumab-fails-to-improve-survival,-increases-toxicities,-in-first%E2%80%91line-treatment-of-patients-with-nsclc/

[160]   Pfizer, “Trial of CP-751, 871 and Erlotinib in Refractory Lung Cancer (NSCLC),” National Library of Medicine (US), ClinicalTrials.gov, Bethesda, 2000. http://clinicaltrials.gov/show/NCT00673049 NLM Identifier: NCT00673049

[161]   F. Atzori, J. Tabernero, A. Cervantes, C. Gamez, J. Rodon, S. Di Cosimo, H. Brown, J. Clark, J. S. Hardwick, R. A. Beckman, W. D. Hanley, K. Hsu, E. Calvo, S. Roselló, R. B. Langdon and J. Baselga, “A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors,” Clinical Cancer Research, Vol. 17, No. 19, 2011, pp. 6304-6312. Doi:10.1158/1078-0432.CCR-10-3336

[162]   Merck, “A Study Evaluating Dalotuzumab (MK0646) in Combination with Erlotinib for Patients with Non-Small Cell Lung Cancer (0646-007),” National Library of Medicine (US), ClinicalTrials.gov, Bethesda, 2000. http://clinicaltrials.gov/show/NCT00654420 NLM Identifier: NCT00654420

[163]   Merck, University of Kansas, “MK-0646 Insulin Growth Factor 1 Receptor Antibody in Stage IIIb or IV Metastatic Non-Squamous Lung Cancer (IMPACT),” National Library of Medicine (US), ClinicalTrials.gov, Bethesda, 2000. http://clinicaltrials.gov/show/NCT00799240 NLM Identifier: NCT00799240

[164]   National Cancer Institute (NCI), “Gemcitabine Hydrochloride and Carboplatin with or without MK-0646 as First-Line Therapy in Treating Patients with Stage IIIB or Stage IV Non-Small Cell Lung Cancer,” National Library of Medicine (US), ClinicalTrials.gov, Bethesda, 2000. http://clinicaltrials.gov/show/NCT00951444 NLM Identifier: NCT00951444

[165]   A. Weickhardt, R. Doebele, A. Oton, J. Lettieri, X. Lu, W. Franklin, M. Varella-Garcia, F. R. Hirsch, M. W. Wynes, H. Youssoufian, A. Adjei and D. R. Camidge, “A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients with Advanced Non-Small Cell Lung Cancer,” Journal of Thoracic Oncology, Vol. 7, No. 2, 2012, pp. 419-426. Doi:10.1097/JTO.0b013e31823c5b11

[166]   National Cancer Institute (NCI), “Paclitaxel, Carboplatin, and Bevacizumab with or without Cixutumumab in Treating Patients with Stage IV or Recurrent Non-Small Cell Lung Cancer,” National Library of Medicine (US), ClinicalTrials.gov, Bethesda, 2000. http://clinicaltrials.gov/show/NCT00955305 NLM Identifier: NCT00955305

[167]   ImClone LLC, “A Study of IMC-A12 (Cixutumumab) with and without Other Standard Chemotherapies in Patients with Lung Cancer Who Have Not Received Chemotherapy Before,” National Library of Medicine (US), ClinicalTrials.gov, Bethesda, 2000. http://clinicaltrials.gov/show/NCT00870870 NLM Identifier: NCT00870870

[168]   National Cancer Institute (NCI), “Erlotinib with or without IMC-A12 in Treating Patients with Stage III or Stage IV Non-Small Cell Lung Cancer,” National Library of Medicine (US), ClinicalTrials.gov, Bethesda, 2000. http://clinicaltrials.gov/show/NCT00778167 NLM Identifier: NCT00778167

[169]   Biogen Idec, “A Study of BIIB022 in Combination with Paclitaxel and Carboplatin in Subjects with Non-Small Cell Lung Cancer,” National Library of Medicine (US), ClinicalTrials.gov, Bethesda, 2000. http://clinicaltrials.gov/show/NCT00970580 NLM Identifier: NCT00970580

[170]   S. S. Ramalingam, D. R. Spigel, D. Chen, M. B. Steins, J. A. Engelman, C.-P. Schneider, S. Novello, W. E. E. Eberhardt, L. Crino, K. Habben, L. Liu, P. A. J?nne, C. M. Brownstein and M. Reck, “Randomized Phase II Study of Erlotinib in Combination with Placebo or R1507, a Monoclonal Antibody to Insulin-Like Growth Factor-1 Receptor, for Advanced-Stage Non-Small-Cell Lung Cancer,” Journal of Clinical Oncology, Vol. 29, No. 34, 2011, pp. 4574-4580. Doi:10.1200/JCO.2011.36.6799

[171]   Amgen, “Phase 1b/2 Study of AMG 479 in Combination with Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer,” National Library of Medicine (US), ClinicalTrials.gov, Bethesda, 2000. http://clinicaltrials.gov/show/NCT00807612 NLM Identifier NCT00807612

[172]   Amgen, “AMG 655 in Combination with AMG 479 in Advanced, Refractory Solid Tumors,” National Library of Medicine (US), ClinicalTrials.gov, Bethesda, 2000. http://clinicaltrials.gov/show/NCT00819169 NLM Identifier: NCT00819169

[173]   S. R. Wiley, K. Schooley, P. J. Smolak, W. S. Din, C. P. Huang, J. K. Nicholl, G. R. Sutherland, T. D. Smith, C. Rauch and C. A. Smith, “Identification and Characterization of a New Member of the TNF Family That Induces Apoptosis,” Immunity, Vol. 3, No. 6, 1995, pp. 673-682. Doi:10.1016/1074-7613(95)90057-8

[174]   L. Pukac, P. Kanakaraj, R. Humphreys, R. Alderson, M. Bloom, C. Sung, T. Riccobene, R. Johnson, M. Fiscella, A. Mahoney, J. Carrell, E. Boyd, X. T. Yao, L. Zhang, L. Zhong, A. von Kerczek, L. Shepard, T. Vaughan, B. Edwards, C. Dobson, T. Salcedo and V. Albert, “HGSETR1, a Fully Human TRAIL-Receptor 1 Monoclonal Antibody, Induces Cell Death in Multiple Tumour Types in Vitro and in Vivo,” British Journal of Cancer, Vol. 92, No. 8, 2005, pp. 1430-1441. Doi:10.1038/sj.bjc.6602487

[175]   D. C. J. Spierings, E. G. E. de Vries, W. Timens, H. J. M. Groen, H. M. Boezen and S. de Jong, “Expression of TRAIL and TRAIL Death Receptors in Stage III Non-Small Cell Lung Cancer Tumors,” Clinical Cancer Research, Vol. 9, No. 9, 2003, pp. 3397-3405.

[176]   W. A. Cooper, M. R. J. Kohonen-Corish, L. Zhuang, B. McCaughan, C. Kennedy, G. Screaton, R. L. Sutherland and C.-S. Lee, “Role and Prognostic Significance of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Death Receptor DR5 in Nonsmall-Cell Lung Cancer and Precursor Lesions,” Cancer, Vol. 113, No. 1, 2008, pp. 135-142. Doi:10.1002/cncr.23528

[177]   T. A. Luster, J. A. Carrell, K. McCormick, D. Sun and R. Humphreys, “Mapatumumab and Lexatumumab Induce Apoptosis in TRAIL-R1 and TRAIL-R2 Antibody-Resistant NSCLC Cell Lines When Treated in Combination with Bortezomib,” Molecular Cancer Therapeutics, Vol. 8, No. 2, 2009, pp. 292-302. Doi:10.1158/1535-7163.MCT-08-0918

[178]   F. A. Greco, P. Bonomi, J. Crawford, K. Kelly, Y. Oh, W. Halpern, L. Lo, G. Gallant and J. Klein, “Phase 2 Study of Mapatumumab, a Fully Human Agonistic Monoclonal Antibody Which Targets and Activates the TRAIL Receptor-1, in Patients with Advanced Non-Small Cell Lung Cancer,” Lung Cancer, Vol. 61, No. 1, 2008, pp. 82-90. Doi:10.1016/j.lungcan.2007.12.011

[179]   J. Von Pawel, J. H. Harvey, D. R. Spigel, M. Dediu, M. Reck, C. L. Cebotaru, E. Kumm, G. Gallant, N. Fox and D. R. Camidge, “A Randomized Phase II Trial of Mapatumumab, a TRAIL-R1 Agonist Monoclonal Antibody, in Combination with Carboplatin and Paclitaxel in Patients with Advanced NSCLC,” Journal of Clinical Oncology, Vol. 28, No. 18, 2010.

[180]   H. A. Wakelee, A. Patnaik, B. I. Sikic, M. Mita, N. L. Fox, R. Miceli, S. J. Ullrich, G. A. Fisher and A. W. Tolcher, “Phase I and Pharmacokinetic Study of Lexatumumab (HGS-ETR2) Given Every 2 Weeks in Patients with Advanced Solid Tumors,” Annals of Oncology, Vol. 21, No. 2, 2010, pp. 376-381. Doi:10.1093/annonc/mdp292

[181]   R. S. Herbst, R. Kurzrock, D. S. Hong, M. Valdivieso, C.-P. Hsu, L. Goyal, G. Juan, Y. C. Hwang, S. Wong, J. S. Hill, G. Friberg and P. M. LoRusso, “A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors,” Clinical Cancer Research, Vol. 16, No. 23, 2010, pp. 5883-5891. Doi:10.1158/1078-0432.CCR-10-0631

[182]   A. Forero-Torres, J. Shah, T. Wood, J. Posey, R. Carlisle, C. Copigneaux, F. R. Luo, S. Wojtowicz-Praga, I. Percent and M. Saleh, “Phase I Trial of Weekly Tigatuzumab, an Agonistic Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5),” Cancer Biother Radiopharm, Vol. 25, No 1, 2010, pp. 13-19. Doi:10.1089/cbr.2009.0673

[183]   T. J. Bayliss, J. T. Smith, M. Schuster, K. H. Dragnev and J. R. Rigas, “A Humanized Anti-IL-6 Antibody (ALD518) in Non-Small Cell Lung Cancer,” Expert Opinion on Biological Therapy, Vol. 11, No. 12, 2011, pp. 1663-1668. Doi:10.1517/14712598.2011.627850

[184]   A. Mantovani, P. Allavena, A. Sica and F. Balkwill, “Cancer-Related Inflammation,” Nature, Vol. 454, No. 7203, 2008, pp. 436-444. Doi:10.1038/nature07205

[185]   N. Songür, B. Kuru, F. Kalkan, C. Ozdilekcan, H. Cakmak and N. Hizel, “Serum Interleukin-6 Levels Correlate with Malnutrition and Survival in Patients with Advanced Non-Small Cell Lung Cancer,” Tumori, Vol. 90, No. 2, 2004, pp. 196-200.

[186]   J. R. Rigas, M. Schuster, S. V. Orlov, B. Milovanovic, B. K. Prabhash, J. T. Smith, et al., “Effect of ALD518, a Humanized Anti-IL-6 Antibody, on Lean Body Mass Loss and Symptoms in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): Results of a Phase II Randomized, Double-Blind Safety and Efficacy Trial,” Journal of Clinical Oncology, Vol. 28, 2010, pp. A7622.

[187]   M. Schuster, J. R. Rigas, S. V. Orlov, B. Milovanovic, K. Prabhash, J. T. Smith, et al., “ALD518, a Humanized Anti-IL-6 Antibody, Treats Anemia in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial,” Journal of Clinical Oncology, Vol. 28, 2010, Article ID: A7631.

[188]   Y. N. Malykh, R. Schauer and L. Shaw, “N-Glycolylneuraminic Acid in Human Tumours,” Biochimie, Vol. 83, No. 7, 2001, pp. 623-634. Doi:10.1016/S0300-9084(01)01303-7

[189]   S. Alfonso, R. M. Diaz, A. de la Torre, E. Santiesteban, F. Aguirre, K. Pérez, J. L. Rodríguez, M. del C. Barroso, A. M. Hernández, D. Toledo, M. R. Gabri, D. F. Alonso, C. Viada, R. E. Gómez, E. Suárez, A. M. Vazquez, R. Perez and A. E. Macias, “1E10 Anti-Idiotype Vaccine in Non-Small Cell Lung Cancer: Experience in Stage IIIb/IV Patients,” Cancer Biology & Therapy, Vol. 6, No. 12, 2007, pp. 1847-1852. Doi:10.4161/cbt.6.12.5000

[190]   F. Robert, E. M. Busby and A. F. LoBuglio, “Chemotherapy Tolerance after Radioimmunotherapy with 90YCC49 Monoclonal Antibody in Patients with Advanced Non-Small Cell Lung Cancer: Clinical Effects and Hematologic Toxicity,” Cancer Biotherapy and Radiopharmaceuticals, Vol. 18, No. 3, 2003, pp. 317-325. Doi:10.1089/108497803322285071

[191]   A. Forero-Torres, S. Shen, H. Breitz, R. B. Sims, D. B. Axworthy, M. B. Khazaeli, K.-H. Chen, I. Percent, S. Besh, A. F. LoBuglio and R. F. Meredith, “Pretargeted Radioimmunotherapy (RIT) with a Novel Anti-TAG-72 Fusion Protein,” Cancer Biotherapy and Radiopharmaceuticals, Vol. 20, No. 4, 2005, pp. 379-390. Doi:10.1089/cbr.2005.20.379

[192]   National cancer institute, City of Hope Medical Center, “Radiolabeled Monoclonal Antibody Therapy in Treating Patients with Stage I-IIIB Non-Small Cell Lung Cancer after Completion of Radiation Therapy Alone or Combined Radiation Therapy and Chemotherapy,” National Library of Medicine (US), ClinicalTrials.gov, Bethesda, 2000. http://clinicaltrials.gov/show/NCT00738452 NLM Identifier NCT00738452

[193]   H. J. Ross, L. L. Hart, P. M. Swanson, M. U. Rarick, R. A. Figlin, A. D. Jacobs, D. E. McCune, A. H. Rosenberg, A. D. Baron, L. E. Grove, M. D. Thorn, D. M. Miller, J. G. Drachman and C. M. Rudin, “A Randomized, Multicenter Study to Determine the Safety and Efficacy of the Immunoconjugate SGN-15 plus Docetaxel for the Treatment of Non-Small Cell Lung Carcinoma,” Lung Cancer, Vol. 54, No. 1, 2006, pp. 69-77. Doi:10.1016/j.lungcan.2006.05.020

[194]   H. Borghaei, K. Alpaugh, G. Hedlund, G. Forsberg, C. Langer, A. Rogatko, R. Hawkins, S. Dueland, U. Lassen and R. B. Cohen, “Phase I Dose Escalation, Pharmacokinetic and Pharmacodynamic Study of Naptumomab Estafenatox Alone in Patients with Advanced Cancer and with Docetaxel in Patients with Advanced Non-Small-Cell Lung Cancer,” Journal of Clinical Oncology, Vol. 27, No. 25, 2009, pp. 4116-4123. Doi:10.1200/JCO.2008.20.2515

 
 
Top